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Summary We have examined the effects of Cyclosporin A (CsA) on growth and polyamine metabolism of
MOLT-4, human T lymphoblastic leukaemia cells to ascertain the role of the polyamine biosynthetic pathway
in the antitumour action of CsA. We observed that CsA had a dose-dependent inhibitory effect on growth of
the cells in vitro, decreasing protein content, cell number and the rate of incorporation of 3H-thymidine into
the cells. However, CsA treatment had no significant effect on intracellular polyamine levels in the cells.
Contrary to previous reports, simultaneous addition of the diamine, putrescine, with CsA did not block or
lessen the growth inhibitory effects of CsA. On the other hand, ornithine decarboxylase activity, the rate
limiting enzyme of polyamine biosynthesis which converts ornithine to putrescine, was decreased by CsA
treatment. This decrease appeared to be reversible and contrasts with the inhibition by x-difluoromethyl-
ornithine, which is irreversible and can be overcome by addition of putrescine. This suppression of ornithine
decarboxylase by CsA is more likely to occur by indirect effects on translation and/or transcription rather than
a direct effect on the enzyme. It may be a contributory factor in the overall antiproliferative effects of CsA but
is more likely to be a response to these growth inhibitory effects rather than a direct effect of the drug.
Cyclosporin A (CsA) is the immunosuppressive agent most
commonly used in the clinical management of allograft rejec-
tion. Its immunosuppressive action has been well docu-
mented (Borel et al., 1977; Granelli-Piperno et al., 1986; Hess
et al., 1982; Thomson et al., 1983) and is attributed to the
inhibition of CD4+ T helper lymphocyte activation and the
production of growth promoting lymphokines. Because of its
specificity for T-cells, it is currently undergoing evaluation as
a treatment for various autoimmune disorders and as an
experimental anti-cancer agent against malignant T-cells.
Various studies have shown selective cytostatic and cytolytic
effects of CsA on malignant T-cells in culture, including
freshly isolated human T-leukaemia/lymphoma cells (Totter-
man et al., 1982; Foa et al., 1986). Morever, we have
previously reported that CsA inhibits the development of the
leukaemic phase in rats injected with the Roser T-cell leu-
kaemia (Thomson et al., 1988). The mechanism(s) underlying
these and other growth inhibitory effects of CsA on cancer
cells (reviewed by McLachlan et al., 1990, and Twentyman,
1988) are not well understood.
Fidelus and Laughter (1986) showed that in the murine
T-cell lymphoma EL4, low doses of CsA inhibited the
activity of ornithine decarboxylase (ODC), the rate limiting
enzyme of polyamine biosynthesis. Furthermore, Saydjari et
al. (1987) reported inhibition of growth of two animal
tumours in vitro by CsA and by ax-difluoromethylornithine
(DFMO), an irreversible inhibitor of ODC. Moreover, they
found that they could overcome the inhibitory effect of both
CsA and DFMO by addition of the diamine putrescine,
suggesting that both drugs were blocking the conversion of
ornithine to putrescine by ODC, resulting in depletion of
intracellular polyamines. On the other hand a study of the
effects of DFMO and CsA on cytolytic T lymphocyte (CTL)
induction (Bowlin et al., 1989) indicated that the drugs may
inhibit different processes required for CTL induction. How-
ever since the naturally occurring polyamines, putrescine,
spermidine and spermine, are known to be essential for
optimal growth and differentiation of cells (Heby, 1981), and
elevated levels are found in many tumours (Kingsnorth et al.,
1984a, b) the possibility that the anti-tumour activity of CsA
may be mediated via depletion of polyamines is worthy of
investigation.
In this study, we show that CsA produces a dose-depen-
dent anti-proliferative effect against MOLT-4 human T-
lymphoblastic leukaemia cells. We also report that CsA
decreases ODC activity but that putrescine, the product of
ODC action does not reverse the growth inhibitory effects of
CsA.
Materials and methods
Chemicals
[Methyl-3H]-thymidine, (25 Ci mmol 1) and DL-[14C]-orni-
thine hydrochloride, (58 mCi mmol-'), were obtained from
Amersham International, UK. Pyridoxal-5-phosphate and
DL-ornithine hydrochloride were obtained from Sigma
Chemical Co., Poole, UK. Dithiothreitol was obtained from
Aldrich Chemical Co. Ltd., Dorset, UK.
Cell culture
MOLT-4, human T-lymphoblastic leukaemia cells, were sup-
plied by the European Collection of Animal Cell Cultures,
Porton Down, Salisbury, UK. The cells were maintained as a
suspension culture at 37°C in an atmosphere of C02/air
(1:19) in RPMI 1640 medium supplemented by 10% foetal
calf serum (Gibco-BRL, Paisley, Scotland).
Effects ofdrugs on cellgrowth
CsA (batch 161412, Sandoz, Basle, Switzerland) was pro-
vided in powder form. It was serially dissolved initially in
absolute ethanol and subsequently, in RPMI-1640. D-L-a-
difluoromethylornithine (DFMO)-HCIH2O (a kind gift from
Merrell Dow Research Institute, Strasbourg, France), pro-
vided as powder, was dissolved in 0.9% w/v saline solution
for addition to cell cultures. Cells were seeded in triplicate
cultures at 3 x I0O cell ml-' in 24 well plates. Drug solutions
were added at time of plating and cells were exposed contin-
uously during the experiments. The final ethanol concentra-
tion was 0.1%. Control cells were treated with drug vehicle.
Protein was measured in mg/well by the method of Lowry et
al. (1951). Cell number and viability was determined using an
Improved Neubauer Haemocytometer and Trypan blue
exclusion.
The rate of [methyl 3H]-thymidine incorporation was also
determined. Cells were given a 1 h pulse of [methyl 3H]-TdR
(0.2 yCi ml-'), harvested mechanically, and the amount of
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radioactivity in the cells was measured by liquid scintillation
counting (Wallace & Keir, 1981).
Generation times (GT) of the cells were calculated accord-
ing to the formula:
GT = log 2 (At) / log (Nt/No)
where At = time in culture between counts, N, = final count
and N. = first count.
Measurement ofpolyamines
Cells were harvested by centrifugation (13,000 r.p.m., 4min)
and the pellet washed twice in ice-cold phosphate buffered
saline (PBS) before extraction of polyamines with 0.2 M
HC104 (Wallace et al., 1984). Polyamines were measured by
the h.p.l.c. methed of Wallace et al. (1988) and protein
content was determined by the method of Lowry et al.
(1951).
Extraction and assay ofornithine decarboxylase (ODC)
Extraction Cells were harvested and washed twice in ice-
cold saline buffer (0.9% w/v NaCl, 100 mM Hepes, mM
Dithiothreitol [DTT]), swollen on ice for 5 min in hypotonic
buffer (100 mM Hepes, 1 mM DTT), then disrupted by homo-
genisation. The homogenate was then centrifuged at 4°C for
20 min at 40,000gav in an MSE Prepspin 50 Ultracentrifuge,
using a 10 x 10 titanium rotor, to remove insoluble cell
debris. The supernatant containing the soluble proteins,
including ODC, was assayed immediately.
Assay The activity of ODC was measured by the release of
[I4C]-CO2 from 14C-ornithine hydrochloride (58 mCi mmolh')
(Russell & Synder, 1968). The reaction mixture contained, in
a final volume of 1 ml, 100 mM Hepes, pH 7.2 at 37°C, 1 mM
DTT, 50 jiM pyridoxal-5-phosphate, 0.2 mM ornithine hydro-
chloride, 0.15 giCi '4C-ornithine hydrochloride and 0.3 ml test
enzyme preparation or 0.3 ml of partially purified E. coli
ODC solution.
Statistics
The significance of differences between the means was cal-
culated using ANOVA/Dunnett's test.
Results
Exposure of MOLT-4 cells to a range of concentrations of
CsA from 0.1Ilg ml-' to 10 jig ml- showed that the growth
of the cells was inhibited in a dose-dependent manner. The
observed effects of CsA treatment were significant decreases
in cell number (Figure 1) and viability (Table I), and in
protein content and 3H-TdR incorporation (Results not
shown). A dose of 10 jg ml' CsA had marked toxic effects
on the cells with cell viability reduced to less than 40% after
96 h in culture. However when the cells were washed after
96 h treatment, fresh medium added, and recovery assessed
by the rate of 3H-TdR incorporation into the cells, it was
observed that the increases in the rate of DNA synthesis with
time in the remaining viable cells in all the treatment groups
were comparable (Table II). The generation times of the
treatment groups were all within 40 ± 6 h (Results not
shown) after the drug was removed and fresh medium added.
Individual polyamine concentrations in cells treated with
1 jig ml-' and 5 jig ml- CsA were virtually unchanged com-
pared to controls after 48 h and 96 h in culture and no
significant alterations in total polyamine content were
observed (Table III).
Simultaneous addition of putrescine at concentrations of
0.1mM, 1mM and IOmM with CsA at ljIgml-' and 5ljg
ml-' did not affect the ability of CsA to inhibit growth of
MOLT-4 cells (Table IV), although in contrast, the growth
inhibitory effects of DFMO were completely reversed by
putrescine at all the concentrations studied.
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Figure 1 Effect of range ofconcentrations of CsA on the growth
of MOLT-4 cells grown in culture over 96 h. Growth measured
as the number of viable cells x 10-6. Means±1 s.d. of triplicate
cultures. 0, Control; 0, I jugml-; V, 2.5jigml-; V,
5jigml'1; 0, lOIgml-'; *P<0.01; #, P<0.05.
Table I Viability of MOLT-4 cells in culture during and after CsA
treatment
Treatment Recovery
48h 96h (% viability) 24h 72h
Control 90 71 Cells 97 78
1 jigml-' CsA 90 69 washed and 87 83
2.5jugml-I CsA 82 65 fresh medium 90 85
5figml- ICsA 84 54 added 78 86
10gml-l CsA 60 38 73 84
% viability of cells measured by trypan blue exclusion.
Table II Recovery of MOLT-4 cells in culture following 96 h treat-
ment with a range of CsA concentrations
Timefrom end oftreatment (h)
96h treatment Oh 24 h 48h 72h
Control 204±22 385± 30 1982±504 1146±70
1lg ml-l CsA 148±47 759±95* 2601 ±80 901 ±223
2.5figml'CsA 227±77 591±42* 2635±177* 1007±81
5fig ml-ICsA 173±67 649±92** 2973± 170** 1089±218
lOfigml-' CsA 204±75 274±41 3522±172** 1094±151
Cells were treated with CsA for 96 h, washed and fresh medium
added. Recovery was assessed by 3H-TdR incorporation into acid-
insoluble fraction of cells (DPM 10-5 viable cells). *P< 0.05,
**P<0.01 compared to controls.
TableIII Polyamineconcentrationsin MOLT-4cellstreatedwithCsA
in vitro
48h 96h
Control
Putrescine 5.99±0.73 0.65±0.16
Spermidine 8.90±0.93 8.57± 1.02
Spermine 8.08±0.53 9.68±0.73
Totals 22.98±2.18 18.88± 1.91
1 gig ml-' CsA
Putrescine 4.24±0.50* 0.75±0.09
Spermidine 8.49±0.55 7.78± 1.60
Spermine 7.28± 0.58 8.35± 1.99
Totals 20.01 ± 1.43 16.89±3.67
5 g ml-'CsA
Putrescine 4.98±0.51 1.70±0.03
Spermidine 10.12±0.68 7.68±0.91
Spermine 9.07±0.82 8.93±0.39
Totals 24.17± 1.96 18.31± 1.20
Amount ofpolyamines expressed in nmol mg- I protein. Results are
means± I s.d. of triplicate assays. *P<0.05 compared to controls.
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Table IV Effects of addition of putrescine with CsA and DFMO
treatments over 96 h in culture
CsA DFMO
IJfgml' 5jfgml- 2.5mM
Control 0.46±0.06 0.49±0.07 0.54±0.04
Drug alone 0.35 0.04* 0.31 0.01* 0.43± 0.01*
0.1 mM Put 0.37 0.02* 0.31 0.01* 0.53±0.02
1 mM Put 0.35±0.01* 0.34 0.03* 0.58±0.04
10mM Put 0.36± 0.02* 0.29 0.04* 0.60±0.02
Results expressed as mg protein/well. Means± 1 s.d. of triplicate
assays. *P< 0.01 compared to controls. Put = putrescine.
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Figure 2 Effects of CsA and DFMO treatment on ODC activity
in MOLT-4 cells in culture, measured by the release of '4C-CO2
from '4C-ornithine. Results are means ± 1 s.d. of triplicate assays.
=I, Control; M, 2.5tLgml ' CsA; _, 5 igml- CsA;
M, 2.5mM DFMO; 1, 5mM DFMO; *P<0.01.
Figure 2 shows that ornithine decarboxylase (ODC) activ-
ity in the MOLT-4 cells was inhibited by treatment with
DFMO (2.5 mM and 5 mM) as expected after 24 h and 48 h
in culture. CsA (2.5ytg ml-' and 5 ,Lgml-') also lowered
ODC activity after 24 h treatment with the higher concentra-
tion being the more effective. After 48 h in culture however,
the ODC activity in the cells treated with 2.5 fig ml-' CsA
appeared to have been fully restored to the same levels as the
controls and the suppression of activity in the cells treated
with 5 ig ml-' was markedly less than at 24 h.
Discussion
We have investigated the effects of CsA on growth and
polyamine metabolism of MOLT-4 cells in culture and com-
pared the results to those obtained with the well established
inhibitor of ODC, oa-DFMO. Our data show that CsA inhib-
its cell growth in a dose-dependent manner demonstrated by
the observed reductions in cell number, cell viability, protein
content and 3H-TdR incorporation in cultures treated with a
range of CsA concentrations.
Polyamines are known to be essential for cell growth and it
has been suggested that depletion of polyamines was a poten-
tial mode of action for the growth inhibitory effects of CsA.
However despite suggestions that polyamine biosynthesis
may be involved in the antitumour action of CsA (reviewed,
McLachlan et al., 1990), we observed no changes in intracel-
lular polyamine content following addition of the drug to
cultures. In contrast to previous reports (Saydjari et al.,
1987) where the growth inhibitory effects of CsA could be
overcome by the addition of putrescine, simultaneous addi-
tion of putrescine with CsA in our model did not reverse the
effects of CsA on cell growth. We were however, able to
reverse the actions of DFMO on intracellular polyamine
content and cell growth by addition of putrescine. The lack
ofeffect of CsA on intracellular polyamine levels is consistent
with the results from our in vivo study (Smart et al., 1989),
where we found that CsA did not deplete polyamine levels,
nor did it enhance the polyamine depletion, seen with
DFMO treatment, in blood mononuclear cells or in various
tissue samples from the tumour hosts.
Despite the lack of a long term effect of CsA on polyamine
content, CsA treatment did decrease ODC activity in MOLT-
4 cells transiently (Table IV), suggesting that either CsA has
a reversible effect on ODC or that there is a decreasing
availability of CsA. Since CsA is known to bind to various
molecules within the cell, such as cyclophilin (Merker &
Handschumacher, 1984; Quesniaux et al., 1988; Ryffel, 1990)
and the 170 Kd membrane P-glycoprotein which functions as
a drug efflux pump in multidrug resistant cells (Foxwell et
al., 1990; Nooter et al., 1990), decreased availability may be a
major reason for the transient effect. DFMO is a 'suicide'
inhibitor of ODC and binds irreversibly to the active site of
the enzyme molecule (Metcalf et al., 1978) thus producing a
direct effect on enzyme activity. On the other hand the
reduction of ODC activity observed in CsA treated cells is
more likely to be a consequence of the antiproliferative
mechanism(s) of CsA on these cells.
It has been proposed by Sigal et al. (1990), that CsA
inhibits Ca2"-associated signal transduction pathways which
may play a major role in the cascade leading to lymphokine
production rather than directly inhibiting lymphokine
mRNA transcription. These signals may also be linked to the
rise in ODC activity which has been shown to be an integral
event regluating lymphocyte DNA synthesis (Kay & Lindsay,
1973; Klimpel et al., 1979).
The intracellular binding protein cyclophilin is generally
thought to be involved in the mode of action of CsA and has
recently been shown to possess peptidyl-prolyl cis-trans iso-
merase (PPIase) activity which is inhibited by CsA binding
(Takahashi et al., 1989; Fischer et al., 1989). Therefore it is
possible that elements involved in the activation cascade may
be 'conformationally' regulated by peptidyl-prolyl bond iso-
merisation. Alternatively, it may also be that intracellular
metabolism of CsA may convert CsA to a derivative which
has no effect on ODC.
Since CsA treatment does not affect intracellular poly-
amine content and its effects cannot be reversed by the
addition of putrescine it seems more likely that the link
between CsA effects and ODC activity is casual rather than
specific and may exist for other enzymes whose functions,
like that of ODC, are so closely linked to cell proliferation.
A recent report by Bowlin et al. (1989), concerning the
effects of CsA and DFMO on the induction of cytolytic T
lymphocytes in vitro and in vivo, demonstrated enhanced
inhibition by combination of the drugs. The explanation
proposed for this result was that the inhibition of interleukin-
2 (IL-2) production by CsA was augmented by a decreased
ability of polyamine-depleted cells to respond to IL-2. We
hope that further studies on the effects of CsA, either on its
own or in combination with DFMO, examining uptake and
intracellular distribution of bound and free drug in different
cellular compartments will help to clarify these observations
and assist in design of possible therapeutic modalities.
We wish to thank the Merrell Dow Research Institute for the kind
gift of DFMO, Sandoz Ltd for CsA and the Cancer Research
Campaign for support in funding the project.
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